Relative efficacy of antilipemic agents in non–high-density lipoprotein cholesterol reduction (Q38007038)

26 August 2017

title

Relative efficacy of antilipemic agents in non–high-density lipoprotein cholesterol reduction (English)

1 reference

26 August 2017

0 references

1 reference

Jennifer Santee

1

1 reference

26 August 2017

Cameron Lindsey

series ordinal

2

1 reference

26 August 2017

Heather Pace

series ordinal

3

1 reference

26 August 2017

publication date

1 August 2012

1 reference

Journal of Pharmacy Practice

26 August 2017

published in

1 reference

26 August 2017

volume

25

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

447-456

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Do triglycerides provide meaningful information about heart disease risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with p

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-dens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Impact of ezetimibe on atherosclerosis: is the jury still out?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Controlled by Pravastatin 40 mg monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012442722

21 January 2018

Identifiers

DOI

10.1177/0897190012442722

1 reference

26 August 2017

1 reference